Stain remover.

Here’s a question. If a breast cancer has low-level HER2 expression via immunohistochemistry (IHC), should they receive HER2 targeted therapy? We’re talking women with IHC of 1+ or 2+ when FISH is subsequently HER2 non-amplified. The standard answer is no, but the NSABP B-47 study randomized 3270 such patients to chemo +/- one year of trastuzumab. At 5 years, these women had no benefit in invasive disease-free survival, distant recurrence-free survival, or overall survival. Confirmed. | Fehrenbacher, J Clin Oncol 2019